Granules India Ltd

Granules India, a midcap pharmaceutical company, experienced notable trading activity on January 30, 2025, with a significant increase in stock value. The stock has shown a strong upward trend over the past two days, outperforming its sector, while also reflecting volatility compared to broader market indices.

Granules India, a midcap pharmaceutical company, experienced notable trading activity on January 30, 2025, with a significant increase in stock value. The stock has shown a strong upward trend over the past two days, outperforming its sector, while also reflecting volatility compared to broader market indices.

Granules India, a midcap pharmaceutical company, has seen a notable decline in its stock, dropping 6.53% on January 28, 2025. This marks three consecutive days of losses, totaling 15.1%. The stock is currently trading below multiple moving averages, indicating a persistent bearish trend.

Granules India, a midcap pharmaceutical company, saw its shares decline by 5.73% on January 27, 2025, continuing a downward trend over two days with a total drop of 7.74%. The stock underperformed its sector and has faced challenges in the current market environment.

Granules India has announced its financial results for Q3 FY24-25, showing a flat performance. For the nine-month period ending December 2024, the company reported a Profit After Tax of Rs 349.48 crore, with a notable improvement in its Debt-Equity Ratio and Debtors Turnover Ratio, despite facing challenges in Profit Before Tax and cash reserves.

Granules India has experienced a revision in its score following a notable decline in stock price on December 13, 2024. The company, a midcap player in the pharmaceutical sector, has been added to MarketsMOJO's list, reflecting ongoing evaluation of its market position and performance indicators. Investors should monitor future trends closely.

Granules India has recently been added to MarketsMOJO's list following a revision in its score, reflecting the stock's positive performance amid favorable market conditions. The company has outperformed its sector and demonstrated consistent gains, indicating a strong position within the pharmaceutical industry. Investors are advised to monitor this stock closely.

Granules India has experienced a revision in its score following a recent decline in stock performance. Despite a brief intraday high, the stock has underperformed relative to market trends and has been added to MarketsMOJO's list. Investors are advised to monitor the company's financial metrics closely. Granules India, a midcap pharmaceutical firm, faced a notable decline in its stock price on December 3rd, 2024, prompting MarketsMOJO to adjust its evaluation. The stock opened at Rs 627.45, reaching an intraday high of Rs 627.45 before dipping to a low of Rs 574. This shift follows three consecutive days of gains. While Granules India's stock remains above its 20-day, 50-day, and 200-day moving averages, it currently lags behind its 5-day and 100-day averages. In comparison to the broader market, the stock has underperformed significantly, with a marked decline over the past month against the Sensex's positive performance. Investors should remain vigilant and consider the company's financial indicators when making decisions.

Granules India has experienced a notable adjustment in its stock evaluation, reflecting its strong market performance. The company has been added to MarketsMOJO's list, highlighting its consistent upward trend and resilience in the pharmaceutical sector. Investors can expect steady performance as the stock maintains a favorable position against market benchmarks.

On November 13, 2024, Granules India's stock price declined by -5.05%, continuing its downward trend for the past three days with a total loss of -8.52%. MarketsMOJO has given a 'Hold' call for the stock. The stock's performance was -3.03% lower than the pharmaceutical and drugs sector and has underperformed the Sensex by -4.90%.

Granules India, a midcap pharmaceutical company, reported a negative performance in the second quarter of fiscal year 2024-2025, with a score of -11. However, the company's debt-equity ratio is at its lowest in the last five half-yearly periods and it has been settling its debtors faster. On the other hand, there are concerns about falling profits and deteriorating liquidity. Investors are advised to hold their position and monitor the company's performance in the upcoming quarters.

On November 6, 2024, Granules India's stock price rose by 5.3%, in line with the pharmaceutical and drugs industry's performance. According to MarketsMOJO, the current stock call for Granules India is 'Hold', based on its recent performance and market trends. The stock has shown a positive trend in the past month, outperforming the Sensex, but investors are advised to do their own research before making any investment decisions.

On October 22, 2024, Granules India's stock price fell by -5.03%, noted by MarketsMOJO who gave a 'Hold' call. The stock has been on a downward trend for 2 days, touching an intraday low of Rs 558.3. However, it still outperforms the sector by -3.76% and has shown positive growth in the past month.

On October 4th, 2024, midcap pharmaceutical company Granules India's stock price dropped by -5.25%, in line with the sector's performance. The stock had been on an upward trend but this decline may indicate a potential reversal. Despite this, the stock is still performing well in the long term and has a 'Hold' rating from MarketsMOJO.

Granules India, a midcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to various factors. These include high management efficiency, healthy long-term growth, and fair valuation. However, the stock's recent performance and decrease in promoter confidence suggest a neutral stance towards the stock. Investors should carefully consider these factors before making any investment decisions.

Granules India, a midcap pharmaceutical company, saw a -5.78% decline in its stock on September 12, 2024, underperforming the sector by -6.14%. This marks a consecutive two-day fall with a total decline of -6.63%. However, the stock's moving averages remain positive, indicating potential for future growth.

Granules India, a leading pharmaceutical company, saw a -5.14% dip in its stock price on September 2nd, 2024. However, according to MarketsMOJO, the company's stock call is currently a 'Buy' and it hit a new 52-week and all-time high on the same day. The stock has consistently outperformed moving averages and has a positive trend, making it a promising investment opportunity.

Granules India, a leading pharmaceutical company in the midcap sector, has reached a new milestone with its stock price hitting a 52-week high of Rs. 724.55 on September 2nd, 2024. Despite underperforming the sector today, the company has consistently traded higher than its moving averages, showcasing its strong and steady performance. With an impressive growth of 135.03% in the past year, Granules India has established itself as a key player in the industry and a promising investment option in the midcap sector.

Granules India, a leading midcap pharmaceutical company, has reached an all-time high stock price of Rs. 724.55 on September 2nd, 2024. This milestone highlights the company's strong performance and growth in the industry. MarketsMOJO has given a 'Buy' call for the stock, and it is currently trading higher than its moving averages. Granules India has also outperformed the Sensex in the past year, making it a promising option for long-term investment.